Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: A randomized controlled study

International Journal of Obesity

Volumn 28, Issue 3, 2004, Pages 378-383

  Ersoz, H O ^a   Ukinc, K ^a   Baykan, M ^a   Erem, C ^a   Durmus, I ^a   Hacihasanoglu, A ^a   Telatar, M ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Heart rate; Hypertension; Metoprolol; Obesity; Sibutramine

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL; PLACEBO; SIBUTRAMINE;

ADULT; ANOREXIA; ANTHROPOMETRY; ARTICLE; BIOCHEMISTRY; BLOOD PRESSURE MONITORING; CARDIOSELECTIVITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; INSOMNIA; INSULIN RESISTANCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL INSTABILITY; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THIRST; VISUAL ANALOG SCALE; WEIGHT REDUCTION; XEROSTOMIA;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTHROPOMETRY; APPETITE DEPRESSANTS; ARRHYTHMIA; CYCLOBUTANES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; METOPROLOL; MIDDLE AGED; OBESITY; PATIENT COMPLIANCE; WEIGHT LOSS;

EID: 1542270112     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0802574     Document Type: Article

References (28)

1. Troiano RP, Frongillo EA, Sobal J, Levitsky DA. The relationship between body weight and mortality: a quantitative analysis of combined information from existing studies. Int Obes Relat Metab Disord 1996; 20: 63-75.
2. Baird IM. Obesity and insurance risk: the insurance industry's viewpoint. PharmacoEconom Suppl 1994; 5 (1): 62-65.
3. McGinnis JM, Foege WH. Actual causes of death in United States. JAMA 1993; 270: 2207-2212.
4. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998; 22: 39-47.
5. Bray GA, Ryan DH, Gordon D. A double blind randomized placebo controlled trial of Sibutramin. Obes Res 1996; 4: 263-270.
6. Hansen D, Astrup A, Toubro S, Finer N, Kopelman P, Hilsted J, Rossner S, Saris W, VanGaal L, James W. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance. Int J Obes Relat Metab Disord 2001; 25 (4): 496-501.
7. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels J, Ryan DH, Schwartz SL, Scheinbaum ML, Seaton TB. Sibutramine produces dose-related weight loss. Obes Res 1999; 7: 189-198.
8. Hypertension Prevention Trial Research Group. The Hypertension Prevention Trial: three-year effects of dietary changes on blood pressure. Arch Intern Med 1990; 150: 153-162.
9. Stevens VJ, Corrigan SA, Obarzanek E, Bernauer E, Cook NR, Hebert P, Mattfeldt-Beman M, Oberman A, Sugars C, Dalcin AT. Weight loss intervention in phase 1 of the trials of hypertension prevention. The TOHP Collaborative Research Group. Arch Intern Med 1993; 153: 849-858.
10. McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian AD. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000; 160: 2185-2191.
11. Hazenberg BP. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine In obese hypertensive patients. Cardiology 2000; 94 (3): 152-158.
12. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999; 106: 179-184.
13. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WH, Van Gaal LF. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356: 2119-2125.
14. Swartz AM, Jeremy Evans M, King GA, Thompson DL. Evaluation of a foot-to-foot bioelectrical impedance analyzer in highly active, moderately active and less active young men. Br J Nutr 2002; 88: 205-210.
15. Jebb SA, Cole TJ, Doman D, Mugratroyd PR, Prentice AP. Evaluation of the novel Tanita body fat analyzer to measure body composition by comparison with four-compartment model. Br J Nutr 2000; 83: 115-122.
16. Mathews DR, Hosker JP, Rudensky A, Turner RC. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 401-411.
17. MacMahon S, Cutler J, Brittain E, Higgins M. Obesity and hypertension: epidemiological and clinical issues. Eur Heart J Suppl 1987; 8/B: 57-70.
18. Cutler JA. Randomized clinical trials of weight reduction in nonhypertensive persons. Ann Epidemiol 1991; 1: 363-370.
19. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762.
20. Stamler J. INTERSALT study findings. Public health and medical care implications. Hypertension 1989; 14: 570-577.
21. Hirsch J, Mackintosh RM, Aronne LJ. The effects of drugs used to treat obesity on the autonomic nervous system. Obes Res 2000; 8: 227-233.
22. Birkenfeld AL, Schroeder C, Boschmann M, Tank J, Franke G, Luft FC, Biaggioni I, Sharma AM, Jordan J. Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 2002; 106: 2459-2465.
23. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001; 37: 250-254.
24. Jequier E, Tappy L. Regulation of body weight in humans. Physiol Rev 1996; 79: 451-480.
25. Jackson HC, Bearham MC, Hutchins LJ, Mazurkiewicz SE, Needham AM, Heal DJ. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol 1997; 121: 1613-1618.
26. Connoley IP, Liu YL, Frost I, Reckless IP, Heal DJ, Stock MJ. Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol 1999; 126: 1487-1495.
27. Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by adrenergic blocking agents: a placebo controlled double-blind, randomized trial. J Hum Hypertens 2002; 16: 13-19.
28. Cuellar GEM, Ruiz AM, Monsalve MCR, Berber A. Six month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. Obes Res 2000; 8: 71-82.